Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2009
Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03918252 (Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma), which is not on this map. Cited by 82 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Who cites it
82 citing papers in PubMed.
- Trial
- Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).Targeted oncology · 2015Trial
- The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Trial
- Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.Journal of translational medicine · 2014Trial
- Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Trial
- Immunotherapy Applications for Thymine Dimers and WT1 Antigen in Renal Cancers: A Comparative Statistical Analysis.Journal of personalized medicine · 2024Article
- Label-Free SERS of Urine Components: A Powerful Tool for Discriminating Renal Cell Carcinoma through Multivariate Analysis and Machine Learning Techniques.International journal of molecular sciences · 2024Article
- suPARnostic: an advanced predictive tool for detecting recurrence in renal cell carcinoma.BMC urology · 2023Article
- ＜Editors' Choice＞ Supernatant from activated omentum accelerates wound healing in diabetic mice wound model.Nagoya journal of medical science · 2023Article
- Contemporary Clinical Definitions, Differential Diagnosis, and Novel Predictive Tools for Renal Cell Carcinoma.Biomedicines · 2022Review
- Panels of mRNAs and miRNAs for decoding molecular mechanisms of Renal Cell Carcinoma (RCC) subtypes utilizing Artificial Intelligence approaches.Scientific reports · 2022Article
- Melanoma therapeutics: a literature review.Journal of biomedical research · 2022Article
- A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden.Nature biomedical engineering · 2021Article
- Ferumoxytol-β-glucan Inhibits Melanoma Growth via Interacting with Dectin-1 to Polarize Macrophages into M1 Phenotype.International journal of medical sciences · 2021Article
- Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers.Nanomaterials (Basel, Switzerland) · 2020Review
- Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study.Frontiers in oncology · 2020Article
- Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies.Therapeutic advances in medical oncology · 2020Review
- Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors.Advances in therapy · 2019Review
- miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.Journal of experimental & clinical cancer research : CR · 2019Article
- Fibronectin Promotes Cell Growth and Migration in Human Renal Cell Carcinoma Cells.International journal of molecular sciences · 2019Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
purposeHigh-dose interleukin-2 (IL-2) induces durable therapeutic responses in a small subset of patients with metastatic melanoma and renal cell carcinoma, but simple pretreatment predictors of response have not been identified. PATIENTS AND
methodsTo identify predictive biomarkers of clinical response, sera from patients treated with high-dose IL-2 were collected for analysis using a customized, multiplex antibody-targeted protein array platform that surveyed expression of soluble factors associated with tumor immunobiology. Soluble factors associated with clinical responses were analyzed using a multivariate permutation test, and survival outcomes were determined using Kaplan-Meier and log-rank tests.
resultsA training set from 10 patients identified 68 potentially relevant soluble factors that were then tested in an independent validation set of 49 patients. Class comparison revealed a cluster of 11 biomarkers that were associated with therapeutic outcome. Vascular endothelial growth factor (VEGF) and fibronectin were identified as independent predictors of response. In particular, high levels of these proteins were correlated with lack of clinical response and decreased overall survival.
conclusionSerum VEGF and fibronectin are easily measured pretreatment biomarkers that could serve to exclude patients unlikely to respond to IL-2 therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.